Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
WILEX Logo
WILEX Growth Score
62
CB Rank
3371002
Heat Score
6
WILEX is a biopharmaceutical company developing drugs and diagnostic agents to detect and treat malignant tumors and cancers.
Founded
obfuscation
PublicPost-IPO Debt Ladenburg, Baden-Wurttemberg, Germany11-50 www.wilex.de
Biopharma
Biotechnology
Health Diagnostics
Overview

WILEX
Total Funding
obfuscation
Growth Score
62
Heat Score
6

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score62
-3 pts
in past quarter
Heat Score 6
-4 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About WILEX

CB Rank
3371002
WILEX is a biopharmaceutical company developing drugs and diagnostic agents to detect and treat malignant tumors and cancers.
Founded
obfuscation
PublicPost-IPO Debt Ladenburg, Baden-Wurttemberg, Germany11-50 www.wilex.de
Biopharma
Biotechnology
Health Diagnostics

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Series C
OBF
in
obfuscation
Venture - Series Unknown
OBF
in
obfuscation

Details

Legal Name Wilex AG
Operating Status Active
Stock Symbol  ETR:WL6
Company Type For Profit
Founders  Olaf Wilhelm
About the Company

WILEX a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II

substance for the treatment of pancreatic and breast cancer. The company's products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.

Phone Number + 49 6203 1009 0
Contact Email info@hdpharma.com
Predictions & Insights

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - WILEX Logo
Post-IPO Debt - WILEX
1
obfuscation
Yorkville AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - WILEX Logo
Post-IPO Debt - WILEX
1
obfuscation
Yorkville AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - WILEX Logo
Post-IPO Debt - WILEX
1
obfuscation
Yorkville AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - WILEX Logo
Post-IPO Debt - WILEX
1
obfuscation
Yorkville AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - WILEX Logo
Post-IPO Debt - WILEX
1
obfuscation
Yorkville AdvisorsPost-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - WILEX Logo
Post-IPO Debt - WILEX
1
obfuscation
Yorkville AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - WILEX Logo
Post-IPO Debt - WILEX
1
obfuscation
Yorkville AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - WILEX Logo
Post-IPO Debt - WILEX
1
obfuscation
Yorkville AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - WILEX Logo
Post-IPO Debt - WILEX
1
obfuscation
Yorkville AdvisorsPost-IPO Debt
obfuscation
Post-IPO Debt - WILEX Logo
Post-IPO Debt - WILEX
1
obfuscation
Yorkville AdvisorsPost-IPO Debt

Investors

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Board Members and Advisors 2

Board Members and Advisors

News
Technology
View Tech Report

Actively Used Products

5WILEX uses 5 technology products and services including Wordpress, jQuery, and  Apache Server, according to G2 Stack.

Active Website Tech Count

2WILEX is actively using 2 technologies for its website, according to BuiltWith. These include CommonCrawl Top 50m.

Total IP

23The intellectual property of WILEX includes 22 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, WILEX has 1 registered trademark in the 'Pharmaceutical, veterinary and sanitary products' class, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is WILEX's headquarters? WILEX is located in Ladenburg, Baden-Wurttemberg, Germany.Who invested in WILEX? WILEX has 5 investors including Yorkville Advisors and  TVM Capital.When was the last funding round for WILEX? WILEX closed its last funding round on
obfuscation
from a Post-IPO Debt round.How much funding has WILEX raised to date? WILEX has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(c22f898 1)
|